BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Davis CL. The antiviral prophylaxis of post-transplant lymphoproliferative disorder. Springer Semin Immunopathol 1998;20:437-53. [DOI: 10.1007/bf00838054] [Cited by in Crossref: 22] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Hopwood P, Crawford DH. The role of EBV in post-transplant malignancies: a review. J Clin Pathol 2000;53:248-54. [PMID: 10823119 DOI: 10.1136/jcp.53.4.248] [Cited by in Crossref: 79] [Cited by in F6Publishing: 65] [Article Influence: 3.6] [Reference Citation Analysis]
2 Trompet E, Temblador A, Gillemot S, Topalis D, Snoeck R, Andrei G. An MHV-68 Mutator Phenotype Mutant Virus, Confirmed by CRISPR/Cas9-Mediated Gene Editing of the Viral DNA Polymerase Gene, Shows Reduced Viral Fitness. Viruses 2021;13:985. [PMID: 34073189 DOI: 10.3390/v13060985] [Reference Citation Analysis]
3 Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie TA, van de Wetering MD, Kremer LC, Leibovici L. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;1:CD004386. [PMID: 22258955 DOI: 10.1002/14651858.cd004386.pub3] [Cited by in Crossref: 65] [Cited by in F6Publishing: 72] [Article Influence: 6.5] [Reference Citation Analysis]